- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Skinvisible signs licensing agreement for two acne products
Las Vegas - Skinvisible, a research and development company focused on dermatology products, has signed a licensing agreement with Embil Pharmaceutical Co. for the right to develop and market two acne products, Earthtimes.org reports.
Las Vegas
- Skinvisible, a research and development company focused on dermatology products, has signed a licensing agreement with Embil Pharmaceutical Co. for the right to develop and market two acne products, Earthtimes.org reports.
The two prescription anti-acne products are formulated with Invisicare,a patented polymer delivery technology, with the active ingredients Clindamycin HCL and Retinoic Acid.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
